Royalty Pharma (RPRX) Notes Payables (2019 - 2023)
Royalty Pharma (RPRX) posted Notes Payables of $9.2 million for Q4 2019.
Powered by 
Analysis
Royalty Pharma (RPRX) Notes Payables (2019 - 2023) Analysis & Trends
Royalty Pharma has reported Notes Payables for 1 years, with the latest figure at $9.2 million in Q4 2019.
- Quarterly Notes Payables changed N/A year-over-year to $9.2 million in Q4 2019, while the trailing twelve-month figure through Dec 2019 was $9.2 million (changed N/A YoY) and the FY2019 annual result came in at $9.2 million, changed N/A from the prior year.
- Notes Payables steadied at $9.2 million in Q4 2019 per RPRX's latest filing.
- Over five years, Notes Payables peaked at $9.2 million in Q4 2019 and troughed at $9.2 million in Q4 2019.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Incyte | 25.44 Bn | 20.91 Bn | 1.57 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2023 | 98.58 Mn |
| Dec 31, 2022 | 94.80 Mn |
| Sep 30, 2022 | 105.73 Mn |
| Jun 30, 2022 | 115.99 Mn |
| Mar 31, 2022 | 116.01 Mn |
| Dec 31, 2021 | 107.93 Mn |
| Sep 30, 2021 | 119.14 Mn |
| Jun 30, 2021 | 117.38 Mn |
| Mar 31, 2021 | 108.84 Mn |
| Dec 31, 2020 | 126.37 Mn |
| Sep 30, 2020 | 135.60 Mn |
| Jun 30, 2020 | 122.80 Mn |
| Dec 31, 2019 | 31.04 Mn |